{"entity": "journal", "iuid": "5620a3a7e50c4701a45cbeec10b564fd", "timestamp": "2026-08-29T04:16:00.438Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Ann%20Surg.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Ann%20Surg"}}, "title": "Ann Surg", "issn": "1528-1140", "issn-l": null, "publications_count": 2, "publications": [{"entity": "publication", "iuid": "8b2336bcf9cf4f82a10ab37967913a60", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/8b2336bcf9cf4f82a10ab37967913a60.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/8b2336bcf9cf4f82a10ab37967913a60"}}, "title": "Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM.", "authors": [{"family": "Olofsson Bagge", "given": "Roger", "initials": "R"}, {"family": "Nelson", "given": "Axel", "initials": "A"}, {"family": "Shafazand", "given": "Amir", "initials": "A"}, {"family": "All-Eriksson", "given": "Charlotta", "initials": "C"}, {"family": "Cahlin", "given": "Christian", "initials": "C"}, {"family": "Elander", "given": "Nils", "initials": "N"}, {"family": "Gustavsson", "given": "Anders", "initials": "A"}, {"family": "Helgadottir", "given": "Hildur", "initials": "H"}, {"family": "Kiilgaard", "given": "Jens Folke", "initials": "JF"}, {"family": "Kinhult", "given": "Sara", "initials": "S"}, {"family": "Ljuslinder", "given": "Ingrid", "initials": "I"}, {"family": "Mattsson", "given": "Jan", "initials": "J"}, {"family": "Rizell", "given": "Magnus", "initials": "M"}, {"family": "Sternby Eilard", "given": "Malin", "initials": "M"}, {"family": "Ullenhag", "given": "Gustav J", "initials": "GJ"}, {"family": "Nilsson", "given": "Jonas A", "initials": "JA"}, {"family": "Ny", "given": "Lars", "initials": "L"}, {"family": "Lindn\u00e9r", "given": "Per", "initials": "P"}], "type": "journal article", "published": "2025-07-01", "journal": {"title": "Ann Surg", "issn": "1528-1140", "volume": "282", "issue": "1", "pages": "100-107", "issn-l": null}, "abstract": "To investigate overall survival (OS) and health-related quality of life (HRQOL) of first-line isolated hepatic perfusion (IHP) compared to best alternative care for patients with uveal melanoma liver metastases.\n\nApproximately half of the patients with uveal melanoma develop metastatic disease, most commonly in the liver, and systemic treatment options are limited. IHP is a locoregional therapy with high response rates but with an unclear effect on OS.\n\nIn this phase III randomized controlled multicenter trial (the SCANDIUM trial), patients with previously untreated isolated uveal melanoma liver metastases were included between 2013 and 2021, with at least 24 months of follow-up. The planned accrual was 90 patients randomized 1:1 to receive a one-time treatment with IHP or best alternative care. Crossover to IHP was not allowed. The primary endpoint was the 24-month OS rate, with the hypothesis of a treatment effect leading to a 50% OS rate in the IHP group compared to 20% in the control group. HRQOL was measured by the EuroQol 5-domains 3-levels (EQ-5D-3L) questionnaire over 12 months.\n\nThe intention-to-treat population included 87 patients randomized to the IHP group [43 patients; 41 (89%) received IHP] or the control group (44 patients). The control group received chemotherapy (49%), immunotherapy (39%), or localized interventions (9%). In the intention-to-treat population, the median progression-free survival was 7.4 months in the IHP group compared with 3.3 months in the control group, with a hazard ratio of 0.21 (95% CI, 0.12-0.36). The 24-month OS rate was 46.5% in the IHP group versus 29.5% in the control group ( P =0.12). The median OS was 21.7 months versus 17.6 months, with a hazard ratio of 0.64 (95% CI, 0.37-1.10). EQ-5D-3L showed a sustained high health status for the IHP group over 12 months, compared to a deteriorating trend in the control group.\n\nFor patients with liver metastases from uveal melanoma, IHP offers high response rates translating to a benefit in progression-free survival including a trend of better HRQOL compared to the control group. However, the primary endpoint of OS at 24 months was not met.", "doi": "10.1097/SLA.0000000000006255", "pmid": "38420778", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12140551"}, {"db": "pii", "key": "00000658-990000000-00798"}], "notes": [], "created": "2026-08-21T12:13:32.036Z", "modified": "2026-08-21T12:13:32.066Z"}, {"entity": "publication", "iuid": "443a4a5bd75a462ca1a68b9d04d7fe4d", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/443a4a5bd75a462ca1a68b9d04d7fe4d.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/443a4a5bd75a462ca1a68b9d04d7fe4d"}}, "title": "Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries.", "authors": [{"family": "Maret-Ouda", "given": "John", "initials": "J"}, {"family": "Santoni", "given": "Giola", "initials": "G"}, {"family": "Wahlin", "given": "Karl", "initials": "K"}, {"family": "Artama", "given": "Miia", "initials": "M"}, {"family": "Brusselaers", "given": "Nele", "initials": "N"}, {"family": "F\u00e4rkkil\u00e4", "given": "Martti", "initials": "M"}, {"family": "Lynge", "given": "Elsebeth", "initials": "E"}, {"family": "Mattsson", "given": "Fredrik", "initials": "F"}, {"family": "Pukkala", "given": "Eero", "initials": "E"}, {"family": "Romundstad", "given": "P\u00e5l", "initials": "P"}, {"family": "Tryggvad\u00f3ttir", "given": "Laufey", "initials": "L"}, {"family": "von Euler-Chelpin", "given": "My", "initials": "M"}, {"family": "Lagergren", "given": "Jesper", "initials": "J"}], "type": "journal article", "published": "2021-12-01", "journal": {"title": "Ann Surg", "issn": "1528-1140", "volume": "274", "issue": "6", "pages": "e535-e540", "issn-l": null}, "abstract": "We aimed to clarify the long-term risk development of EAC after antireflux surgery.\n\nGastroesophageal reflux disease (GERD) increases EAC risk, but whether antireflux surgery prevents EAC is uncertain.\n\nMultinational, population-based cohort study including individuals with GERD from all 5 Nordic countries in 1964-2014. First, EAC risk after antireflux surgery in the cohort was compared with the corresponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence intervals (95% CIs). Second, multivariable Cox proportional hazards regression, providing hazard ratios (HRs) with 95% CIs, compared EAC risk in GERD patients with antireflux surgery with those with nonsurgical treatment.\n\nAmong 942,071 GERD patients, 48,863 underwent surgery and 893,208 did not. Compared to the corresponding background population, EAC risk did not decrease after antireflux surgery [SIR 4.90 (95% CI 3.62-6.47) 1-<5 years and SIR 4.57 (95% CI 3.44-5.95) \u226515 years after surgery]. Similarly, no decrease was found for patients with severe GERD (esophagitis or Barrett esophagus) after surgery [SIR 6.09 (95% CI 4.39-8.23) 1-<5 years and SIR = 5.27 (95% CI 3.73-7.23) \u226515 years]. The HRs of EAC were stable comparing the surgery group with the nonsurgery group with GERD [HR 1.71 (95% CI 1.26-2.33) 1-<5 years and HR 1.69 (95% CI 1.24-2.30) \u226515 years after treatment], or for severe GERD [HR 1.56 (95% CI 1.11-2.20) 1-<5 years and HR 1.57 (95% CI 1.08-2.26) \u226515 years after treatment].\n\nSurgical treatment of GERD does not seem to reduce EAC risk.", "doi": "10.1097/SLA.0000000000003709", "pmid": "31800492", "labels": [], "xrefs": [{"db": "pii", "key": "00000658-202112000-00042"}], "notes": [], "created": "2026-08-21T12:13:30.110Z", "modified": "2026-08-21T12:13:30.155Z"}], "created": "2026-08-21T12:13:30.119Z", "modified": "2026-08-21T12:13:30.120Z"}